JP2023547728A5 - - Google Patents

Info

Publication number
JP2023547728A5
JP2023547728A5 JP2023527970A JP2023527970A JP2023547728A5 JP 2023547728 A5 JP2023547728 A5 JP 2023547728A5 JP 2023527970 A JP2023527970 A JP 2023527970A JP 2023527970 A JP2023527970 A JP 2023527970A JP 2023547728 A5 JP2023547728 A5 JP 2023547728A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
viral infection
aat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547728A (ja
Filing date
Publication date
Priority claimed from EP20206287.3A external-priority patent/EP3995130A1/en
Application filed filed Critical
Priority claimed from PCT/EP2021/080936 external-priority patent/WO2022096708A1/en
Publication of JP2023547728A publication Critical patent/JP2023547728A/ja
Publication of JP2023547728A5 publication Critical patent/JP2023547728A5/ja
Pending legal-status Critical Current

Links

JP2023527970A 2020-11-06 2021-11-08 間葉系幹細胞由来の細胞外小胞およびアルファ-1アンチトリプシンを含むウイルス感染症治療用組成物 Pending JP2023547728A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20206287.3A EP3995130A1 (en) 2020-11-06 2020-11-06 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections
EP20206287.3 2020-11-06
EP21159620 2021-02-26
EP21159620.0 2021-02-26
PCT/EP2021/080936 WO2022096708A1 (en) 2020-11-06 2021-11-08 A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2023547728A JP2023547728A (ja) 2023-11-13
JP2023547728A5 true JP2023547728A5 (cg-RX-API-DMAC7.html) 2024-11-12

Family

ID=78806458

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527970A Pending JP2023547728A (ja) 2020-11-06 2021-11-08 間葉系幹細胞由来の細胞外小胞およびアルファ-1アンチトリプシンを含むウイルス感染症治療用組成物

Country Status (7)

Country Link
US (1) US20230414730A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240323A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023547728A (cg-RX-API-DMAC7.html)
AU (1) AU2021375735A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200691A1 (cg-RX-API-DMAC7.html)
IL (1) IL302649A (cg-RX-API-DMAC7.html)
WO (1) WO2022096708A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
IL320107A (en) 2019-02-07 2025-06-01 Direct Biologics Llc Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds
WO2021011935A1 (en) 2019-07-18 2021-01-21 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
MX2022013301A (es) 2020-04-22 2023-02-14 Direct Biologics Llc Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa.
CN115381857B (zh) * 2022-10-28 2023-02-03 上海市东方医院(同济大学附属东方医院) 间充质干细胞在制备治疗hpv持续感染的药物中的应用
US20240309329A1 (en) * 2023-03-17 2024-09-19 MAM Holdings of West Florida, L.L.C. Mesenchymal stem cell-derived exosome drug delivery for cancer and other disorders
WO2025226276A1 (en) 2024-04-25 2025-10-30 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
WO2025227013A1 (en) * 2024-04-26 2025-10-30 Musc Foundation For Research Development Extracellular vesicles from alpha-1 antitrypsin overexpressing cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376633A (en) * 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
JP4426179B2 (ja) * 2000-12-18 2010-03-03 アライバ ファーマシューティカルズ,インコーポレイティド 多機能性プロテアーゼインヒビターおよびそれらの疾患治療における使用
WO2009005877A2 (en) * 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-i antitrypsin having no significant serine protease inhibitor activity
JP5727458B2 (ja) 2009-04-13 2015-06-03 アプセト ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフトApceth Gmbh & Co. Kg 改変間葉系幹細胞及びそれを使用した腫瘍の治療方法
KR102063069B1 (ko) * 2011-03-11 2020-01-08 칠드런'즈 메디컬 센터 코포레이션 중간엽 줄기 세포 엑소솜에 관련된 방법 및 조성물
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
WO2016146819A1 (en) * 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
WO2020092448A1 (en) * 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders

Similar Documents

Publication Publication Date Title
US8387895B2 (en) Inhalation nebulizer
Wildhaber et al. Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers
US20070267010A1 (en) Methods and systems for operating an aerosol generator
US20120080030A1 (en) Mouthpiece and Flow Rate Controller for Intrapulmonary Delivery Devices
JP2008536546A5 (cg-RX-API-DMAC7.html)
CA2425489A1 (en) Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
US20210353650A1 (en) Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation
CN115955965A (zh) 用于治疗、改善或预防微生物感染的制造产品和方法
JP2024515446A5 (cg-RX-API-DMAC7.html)
JP2023544685A (ja) 吸入ルートを介するソフトミスト吸入器又は振動型メッシュ式噴霧器を用いた新型コロナウイルス感染症を含むウイルス性肺疾患の治療における抗ウイルス性、抗マラリア性及び/又は粘液溶解性を備える活性物質の使用
IT202000005026A1 (it) Lattoferrina per uso inalatorio ad azione antivirale
CN112791097A (zh) 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法
Dolovich Aerosol delivery to children: what to use, how to choose
MXPA04002066A (es) Farmacos contra influenza.
WO2022034557A1 (en) Intravenous and oral inhalation anti-viral compositions and methods
JP2019504040A (ja) 中等度〜重度のインフルエンザの処置
CA2701388C (en) Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
JP2010189301A (ja) 新型インフルエンザ感染症に対する医薬組成物およびその利用
JP2024546179A5 (cg-RX-API-DMAC7.html)
WO2022063320A1 (zh) 一种抑制呼吸道病毒的组合物及呼吸道病毒防治方法
O′ Callaghan Targeting drug delivery to the lungs by inhalation
JP2002030000A (ja) 風邪根本治療法
EP3906934B1 (en) Application of dalargin for the prevention of viral respiratory infections and prevention of the development of complications during viral respiratory infections
EP4005565A1 (en) Novel uses of adamantane derivatives
Businco et al. Efficacy of Mucoregulatory Therapies Administered by Micronized Vaporization Compared to Nasal Spray in the Treatment of Upper Airway Respiratory Inflammation